Michael E Klepser

List of Publications by Year
in descending order

43 papers	2,837 citations	201674 27 h-index	265206 42 g-index
43 all docs	43 docs citations	43 times ranked	1938 citing authors

#	Article	IF	Citations
1	Impact of COVID-19 on prevalence of community pharmacies as CLIA-Waived facilities. Research in Social and Administrative Pharmacy, 2021, 17, 1574-1578.	3.0	18
2	Pharmacist Prescriptive Authority for Acne: An Evidence-Based Approach to Policy. Innovations in Pharmacy, 2021, 12, 11.	0.6	9
3	The impact of the COVID-19 pandemic on addressing common barriers to pharmacy-based point-of-care testing. Expert Review of Molecular Diagnostics, 2021, 21, 751-755.	3.1	3
4	Pharmacy-Based Assessment and Management of Herpes Labialis (Cold Sores) with Antiviral Therapy. Innovations in Pharmacy, 2020, 11, 3.	0.6	10
5	Community pharmacy-based point-of-care testing: A case study of pharmacist-physician collaborative working relationships. Research in Social and Administrative Pharmacy, 2018, 14, 112-115.	3.0	13
6	Observation of a Pharmacist-Conducted Group A Streptococcal Pharyngitis Point-of-Care Test: A Time and Motion Study. Journal of Pharmacy Practice, 2018, 31, 284-291.	1.0	17
7	Utilization of influenza and streptococcal pharyngitis point-of-care testing in the community pharmacy practice setting. Research in Social and Administrative Pharmacy, 2018, 14, 356-359.	3.0	50
8	Point-of-care testing in the pharmacy: how is the field evolving?. Expert Review of Molecular Diagnostics, 2018, 18, 5-6.	3.1	12
9	Pharmacy-based management of influenza: lessons learned from research. International Journal of Pharmacy Practice, 2018, 26, 573-578.	0.6	19
10	The Roles of Pharmacy Schools in Bridging the Gap Between Law and Practice. American Journal of Pharmaceutical Education, 2018, 82, 6577.	2.1	10
11	An update on community pharmacies as CLIA-waived facilities. Research in Social and Administrative Pharmacy, 2016, 12, 666-667.	3.0	9
12	U.S. community pharmacies as CLIA-waived facilities: Prevalence, dispersion, and impact on patient access to testing. Research in Social and Administrative Pharmacy, 2016, 12, 614-621.	3.0	33
13	Pharmacological and Host Considerations in the Selection of Dose and Duration of Azole Therapy for Adult Patients. Current Fungal Infection Reports, 2012, 6, 127-132.	2.6	0
14	Safety and Efficacy Data for High-Dose Caspofungin. Current Fungal Infection Reports, 2010, 4, 59-61.	2.6	1
15	Consensus Summary of Aerosolized Antimicrobial Agents: Application of Guideline Criteria. Pharmacotherapy, 2010, 30, 562-584.	2.6	77
16	Safety of aerosolized amphotericin B. Expert Opinion on Drug Safety, 2007, 6, 523-532.	2.4	478
17	CandidaResistance and Its Clinical Relevance. Pharmacotherapy, 2006, 26, 68S-75S.	2.6	43
18	In Vitro Pharmacodynamics of Amphotericin B, Itraconazole, and Voriconazole againstAspergillus,Fusarium, andScedosporiumspp. Antimicrobial Agents and Chemotherapy, 2005, 49, 945-951.	3.2	111

#	Article	IF	Citations
19	In Vitro Activity of Micafungin (FK-463) against Candida spp.: Microdilution, Time-Kill, and Postantifungal-Effect Studies. Antimicrobial Agents and Chemotherapy, 2002, 46, 3846-3853.	3.2	146
20	Rates and Extents of Antifungal Activities of Amphotericin B, Flucytosine, Fluconazole, and Voriconazole against Candida lusitaniae Determined by Microdilution, Etest, and Time-Kill Methods. Antimicrobial Agents and Chemotherapy, 2002, 46, 578-581.	3.2	48
21	Amphotericin B in Lung Transplant Recipients. Annals of Pharmacotherapy, 2002, 36, 167-169.	1.9	8
22	Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagnostic Microbiology and Infectious Disease, 2002, 43, 13-17.	1.8	94
23	The Rationale for Aerosolized Antibiotics. Pharmacotherapy, 2002, 22, 71S-79S.	2.6	34
24	Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagnostic Microbiology and Infectious Disease, 2001, 41, 121-126.	1.8	36
25	Antifungal Resistance AmongCandidaSpecies. Pharmacotherapy, 2001, 21, 124S-132S.	2.6	50
26	Comparative Bactericidal Activities of Ciprofloxacin, Clinafloxacin, Grepafloxacin, Levofloxacin, Moxifloxacin, and Trovafloxacin against Streptococcus pneumoniae in a Dynamic In Vitro Model. Antimicrobial Agents and Chemotherapy, 2001, 45, 673-678.	3.2	47
27	Assessment of Patients' Perceptions and Beliefs Regarding Herbal Therapies. Pharmacotherapy, 2000, 20, 83-87.	2.6	110
28	Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology. Antimicrobial Agents and Chemotherapy, 2000, 44, 1917-1920.	3.2	101
29	In Vitro Pharmacodynamic Characteristics of Nystatin Including Time-Kill and Postantifungal Effect. Antimicrobial Agents and Chemotherapy, 2000, 44, 2887-2890.	3.2	37
30	Postantifungal Effects of Echinocandin, Azole, and Polyene Antifungal Agents against Candida albicans and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy, 2000, 44, 1108-1111.	3.2	175
31	In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methodsâ˜†. Diagnostic Microbiology and Infectious Disease, 2000, 36, 101-105.	1.8	40
32	Unsafe and potentially safe herbal therapies. American Journal of Health-System Pharmacy, 1999, 56, 125-138.	1.0	175
33	The changing face of nosocomial candidemia: epidemiology, resistance, and drug therapy. American Journal of Health-System Pharmacy, 1999, 56, 525-533.	1.0	37
34	In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diagnostic Microbiology and Infectious Disease, 1999, 33, 75-80.	1.8	140
35	Therapy ofCandidaInfections: Susceptibility Testing, Resistance, and Therapeutic Options. Annals of Pharmacotherapy, 1998, 32, 1353-1361.	1.9	20
36	Influence of Test Conditions on Antifungal Time-Kill Curve Results: Proposal for Standardized Methods. Antimicrobial Agents and Chemotherapy, 1998, 42, 1207-1212.	3.2	260

#	Article	IF	Citations
37	Assessment of Antifungal Activities of Fluconazole and Amphotericin B Administered Alone and in Combination against Candida albicans by Using a Dynamic In Vitro Mycotic Infection Model. Antimicrobial Agents and Chemotherapy, 1998, 42, 1382-1386.	3.2	87
38	Evaluation of Endpoints for Antifungal Susceptibility Determinations with LY303366. Antimicrobial Agents and Chemotherapy, 1998, 42, 1387-1391.	3.2	43
39	Variation in Electrophoretic Karyotype and Antifungal Susceptibility of Clinical Isolates of Cryptococcus neoformans at a University-Affiliated Teaching Hospital from 1987 to 1994. Journal of Clinical Microbiology, 1998, 36, 3653-3656.	3.9	25
40	Drug Treatment of HIV-Related Opportunistic Infections. Drugs, 1997, 53, 40-73.	10.9	56
41	Growth medium effect on the antifungal activity of LY 303366. Diagnostic Microbiology and Infectious Disease, 1997, 29, 227-231.	1.8	23
42	Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?. American Journal of Health-System Pharmacy, 1997, 54, 2569-2584.	1.0	62
43	Antifungal dynamics of LY 303366, an investigational echinocandin B analog, against Candida ssp.. Diagnostic Microbiology and Infectious Disease, 1996, 26, 125-131.	1.8	70